WINTON GROUP Ltd Takes Position in Parabilis Medicines, Inc. $PBLS

Key Points

• WINTON GROUP Ltd acquired 34,900 shares of Parabilis Medicines in the second quarter, valued at approximately $955,000. Several other institutional investors also initiated positions, including ICONIQ Capital, which invested about $9.58 million.
• Analyst sentiment is generally positive, with a consensus “Moderate Buy” rating and an average price target of $41.67, although Weiss Ratings initiated coverage with a sell rating.
• PBLS shares opened at $36.88, compared with a 52-week range of $24.51 to $41.49. Parabilis reported a quarterly loss of $2.32 per share—well below the expected $0.16 loss—and revenue of only $150,000.

WINTON GROUP Ltd acquired a new stake in shares of Parabilis Medicines, Inc. (NASDAQ:PBLS - Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 34,900 shares of the company's stock, valued at approximately $955,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in PBLS. Persistent Asset Partners Ltd purchased a new position in Parabilis Medicines during the second quarter valued at approximately $113,000. Alyeska Investment Group L.P. bought a new stake in shares of Parabilis Medicines during the 2nd quarter valued at $274,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in shares of Parabilis Medicines during the 2nd quarter valued at $526,000. Squarepoint Ops LLC bought a new position in Parabilis Medicines in the 2nd quarter worth $1,327,000. Finally, ICONIQ Capital LLC bought a new position in Parabilis Medicines in the 2nd quarter worth $9,580,000.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on PBLS. Weiss Ratings started coverage on Parabilis Medicines in a research note on Friday, September 4th. They issued a "sell (d)" rating for the company. Leerink Partners started coverage on Parabilis Medicines in a research note on Monday, July 6th. They issued an "outperform" rating and a $40.00 price objective for the company. Evercore began coverage on Parabilis Medicines in a research note on Monday, July 6th. They issued an "outperform" rating for the company. Guggenheim began coverage on Parabilis Medicines in a research report on Monday, July 6th. They set a "buy" rating and a $40.00 target price for the company. Finally, Lifesci Capital raised Parabilis Medicines to a "strong-buy" rating in a research note on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $41.67.

Parabilis Medicines Price Performance

Shares of NASDAQ:PBLS opened at $36.88 on Monday. Parabilis Medicines, Inc. has a 52 week low of $24.51 and a 52 week high of $41.49. The business has a fifty day simple moving average of $35.13.

Parabilis Medicines (NASDAQ:PBLS - Get Free Report) last announced its earnings results on Thursday, August 13th. The company reported ($2.32) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by ($2.16). The firm had revenue of $0.15 million during the quarter. As a group, research analysts expect that Parabilis Medicines, Inc. will post -2.05 EPS for the current fiscal year.

Parabilis Medicines Company Profile

Parabilis Medicines Inc is a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. Parabilis Medicines Inc is based in CAMBRIDGE, Mass.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.